Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Aug 12;9 Suppl 1(Suppl 1):28.
doi: 10.1186/s12920-016-0196-3.

SFRP1 is a possible candidate for epigenetic therapy in non-small cell lung cancer

Y-H Taguchi  1 , Mitsuo Iwadate  2 , Hideaki Umeyama  2
Affiliations

SFRP1 is a possible candidate for epigenetic therapy in non-small cell lung cancer

Y-H Taguchi et al. BMC Med Genomics. .

Abstract

Background: Non-small cell lung cancer (NSCLC) remains a lethal disease despite many proposed treatments. Recent studies have indicated that epigenetic therapy, which targets epigenetic effects, might be a new therapeutic methodology for NSCLC. However, it is not clear which objects (e.g., genes) this treatment specifically targets. Secreted frizzled-related proteins (SFRPs) are promising candidates for epigenetic therapy in many cancers, but there have been no reports of SFRPs targeted by epigenetic therapy for NSCLC.

Methods: This study performed a meta-analysis of reprogrammed NSCLC cell lines instead of the direct examination of epigenetic therapy treatment to identify epigenetic therapy targets. In addition, mRNA expression/promoter methylation profiles were processed by recently proposed principal component analysis based unsupervised feature extraction and categorical regression analysis based feature extraction.

Results: The Wnt/β-catenin signalling pathway was extensively enriched among 32 genes identified by feature extraction. Among the genes identified, SFRP1 was specifically indicated to target β-catenin, and thus might be targeted by epigenetic therapy in NSCLC cell lines. A histone deacetylase inhibitor might reactivate SFRP1 based upon the re-analysis of a public domain data set. Numerical computation validated the binding of SFRP1 to WNT1 to suppress Wnt signalling pathway activation in NSCLC.

Conclusions: The meta-analysis of reprogrammed NSCLC cell lines identified SFRP1 as a promising target of epigenetic therapy for NSCLC.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Hierarchical clustering of PCs. Vertical axes represent distance that is negative signed absolute correlation coefficients between PCs. PCs with “M” indicate promoter methylation and those without “M” were computed from gene expression
Fig. 2
Fig. 2
Protein complex. a WNT1 (cyan) + SFRP1 (light green) by Fiberdock + ZDOCK, b WNT8 (cyan) + CRD of FZ8 (light green) by Fiberdock + ZDOCK, c WNT1(cyan) + SFRP1(light green) by GROMACS (time = 2 ns), d WNT8 (cyan) + CRD of Fz8 (light green) in PDB (PDB ID: 4F0A)
Fig. 3
Fig. 3
RMSD for GROMACS MD for those from 0 ns to 1 ns and those from 1 ns to 2 ns
See this image and copyright information in PMC

References

    1. Mehta A, et al. Epigenetics in lung cancer diagnosis and therapy. Cancer Metastasis Rev. 2015;34(2):229–41. doi: 10.1007/s10555-015-9563-3. - DOI - PubMed
    1. Huffman K, Martinez ED. Pre-clinical studies of epigenetic therapies targeting histone modifiers in lung cancer. Front Oncol. 2013;3:235. doi: 10.3389/fonc.2013.00235. - DOI - PMC - PubMed
    1. Momparler RL. Epigenetic therapy of non-small cell lung cancer using decitabine (5-aza-2’-deoxycytidine) Front Oncol. 2013;3:188. doi: 10.3389/fonc.2013.00188. - DOI - PMC - PubMed
    1. Jakopovic M, et al. Targeting the epigenome in lung cancer: expanding approaches to epigenetic therapy. Front Oncol. 2013;3:261. doi: 10.3389/fonc.2013.00261. - DOI - PMC - PubMed
    1. Vendetti FP, et al. Evaluation of azacitidine and entinostat as sensitization agents to cytotoxic chemotherapy in preclinical models of non-small cell lung cancer. Oncotarget. 2015;6(1):56–70. - PMC - PubMed

Publication types

MeSH terms

Substances